Can Reata Pharmaceuticals Inc – Class A (NASDAQ:RETA)’s Tomorrow be Different? The Stock Had Increase in Shorts

June 7, 2018 - By Marie Mckinney

The stock of Reata Pharmaceuticals Inc – Class A (NASDAQ:RETA) registered an increase of 15.69% in short interest. RETA’s total short interest was 1.98 million shares in June as published by FINRA. Its up 15.69% from 1.71 million shares, reported previously. With 214,800 shares average volume, it will take short sellers 9 days to cover their RETA’s short positions. The short interest to Reata Pharmaceuticals Inc – Class A’s float is 10.89%.

The stock decreased 3.10% or $1.1376 during the last trading session, reaching $35.5224. About 105,272 shares traded. Reata Pharmaceuticals, Inc. (NASDAQ:RETA) has risen 19.31% since June 7, 2017 and is uptrending. It has outperformed by 6.74% the S&P500.

Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on identifying, developing, and commercializing product candidates for patients with rare and life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company has market cap of $929.43 million. The Company’s lead product candidates include Bardoxolone methyl, which is in Phase III clinical trial for the treatment of pulmonary arterial hypertension and associated with connective tissue disease, as well as in Phase II clinical trial for the treatment of pulmonary hypertension due to interstitial lung disease and pulmonary arterial hypertension; and Omaveloxolone that is in Phase II clinical trial for the treatment of FriedreichÂ’s ataxia, mitochondrial myopathies, and metastatic melanoma. It currently has negative earnings. The firm was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005.

More notable recent Reata Pharmaceuticals, Inc. (NASDAQ:RETA) news were published by: Seekingalpha.com which released: “Reata Pharmaceuticals’ (RETA) CEO Warren Huff on Q1 2018 Results – Earnings Call Transcript” on May 13, 2018, also Benzinga.com with their article: “Benzinga’s Daily Biotech Pulse: Organovo Falls On Earnings; Celgene Gets New CFO” published on June 01, 2018, Nasdaq.com published: “Reata Announces That Kyowa Hakko Kirin Initiated Ayame, a Phase 3 Trial of Bardoxolone Methyl for the Treatment of …” on June 04, 2018. More interesting news about Reata Pharmaceuticals, Inc. (NASDAQ:RETA) were released by: Benzinga.com and their article: “Benzinga’s Daily Biotech Pulse: Biomarin Gets FDA Nod, Amarin Settles with Teva, Merck’s Cancer Drug Review …” published on May 25, 2018 as well as Nasdaq.com‘s news article titled: “Report: Developing Opportunities within AG Mortgage Investment Trust, Associated Banc-Corp, Reata Pharmaceuticals …” with publication date: May 18, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: